Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02532764 |
|
Recruitment Status :
Completed
First Posted : August 26, 2015
Results First Posted : February 6, 2019
Last Update Posted : February 6, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: QR-010 Drug: Placebo | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 70 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis |
| Study Start Date : | June 2015 |
| Actual Primary Completion Date : | September 14, 2017 |
| Actual Study Completion Date : | September 14, 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: QR-010
QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
|
Drug: QR-010
Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton |
|
Placebo Comparator: Placebo
Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
|
Drug: Placebo
Normal Saline |
- Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]Number of subjects experiencing at least one treatment emergent adverse events (TEAEs)
- Severity of Treatment Emergent Adverse Events From Baseline Through End of Study [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]
Assessment of severity of treatment emergent adverse events (TEAEs).
Severity is graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Modified for CF (CTCAE v4.03). For events not present in this listing the following grading was applied:
Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Moderate: Minimal, local, or noninvasive intervention indicated; discomfort sufficient to reduce or interfere with daily activities; Severe: Medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization may be indicated; disabling; limits self-care with significant interference with daily activities; incapacitating with inability to perform self care activities of daily living; Life-threatening: Urgent intervention indicated; immediate risk of death.
- Incidence of Subjects Experiencing Dose-Limiting Toxicities (DLT) in Each Dose Cohort From Baseline Through End of Study Visit. [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]DLT's were defined as an allergic reaction, acute bronchospasm or acute AEs of interest requiring (immediate) medical intervention.
- Number of Subjects With Abnormalities Reported Regarding Laboratory Parameters, Vital Signs, ECG, Spirometry, and Physical Findings. [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]Number of subjects experiencing at least one abnormality for the categories laboratory parameters, vital signs, ECG, spirometry and physical findings that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely.
- Maximum Serum Concentration [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]Cmax: QR-010 maximum serum concentrations
- Time to Maximum Serum Concentration [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]Tmax: Time to Cmax of QR-010 serum concentrations.
- Terminal Half-life (T1/2) [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]The terminal elimination half-life will be estimated by non-linear regression analysis of the terminal elimination slope
- Area Under the Curve to Final Sample [AUC(0-last)] [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]Area under the curve to the final sample with a concentration greater than lower limit of quantification (LLQ) will be calculated using the linear trapezoidal method
- Area Under the Curve to Infinity [AUC(0-∞)] [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]AUC0-∞: Area under the curve to infinity will be calculated based on the last observed concentration Clast(obs) using formula: AUC0-∞=AUClast+Clast(obs)/λz
- Serum Clearance (CL) [ Time Frame: 8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts ]CL: Serum clearance will be estimated using the formula: CL = Dose/AUC0-∞.
- Adjusted Mean Change From Baseline in CFQ-R RSS [ Time Frame: Day 15, Day 33, Day 54 ]Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS). A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo [ Time Frame: Day 15, Day 33, Day 54 ]
Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in CFQ-R RSS (Subgroup ppFEV1 <90% at Baseline) [ Time Frame: Day 15, Day 33, Day 54 ]
Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo (Subgroup ppFEV1 <90% at Baseline) [ Time Frame: Day 15, Day 33, Day 54 ]
Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in ppFEV1 [ Time Frame: Day 15, Day 33, Day 54 ]Exploratory efficacy parameter, as measured by spirometry, and expressed in percent predicted FEV1 (ppFEV1). Mean values reported refer to ''adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo [ Time Frame: Day 15, Day 33, Day 54 ]Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1 (ppFEV1). Mean values reported refer to''difference vs placebo in adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in ppFEV1 (Subgroup ppFEV1 <90% at Baseline) [ Time Frame: Day 15, Day 33, Day 54 ]Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''adjusted mean change from baseline'' values.
- Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo (Subgroup ppFEV1 <90% at Baseline) [ Time Frame: Day 15, Day 33, Day 54 ]Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test (sweat chloride) of > 60 mmol/L
- Confirmation of CFTR gene mutations homozygous for the ΔF508 mutation
- Body mass index (BMI) ≥ 17 kg/m2
- Non-smoking for a minimum of two years
- FEV1 ≥70% of predicted normal for age, gender, and height, at Screening
- Stable lung function
- Adequate hepatic and renal function
Exclusion Criteria:
- Breast-feeding or pregnant
- Use of lumacaftor or ivacaftor
- Use of any investigational drug or device
- History of lung transplantation
- Hemoptysis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02532764
Show 27 study locations
| Principal Investigator: | Stuart Elborn, MD | Trust and Queen's University Belfast |
Documents provided by ProQR Therapeutics:
| Responsible Party: | ProQR Therapeutics |
| ClinicalTrials.gov Identifier: | NCT02532764 |
| Other Study ID Numbers: |
PQ-010-001 |
| First Posted: | August 26, 2015 Key Record Dates |
| Results First Posted: | February 6, 2019 |
| Last Update Posted: | February 6, 2019 |
| Last Verified: | January 2019 |
|
cystic fibrosis ΔF508 RNA therapies antisense oligonucleotide |
CFTR F508del CF RNA therapy |
|
Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases |